These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11440030)

  • 1. Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis.
    Wu H; Dimitrakopoulou-Strauss A; Heichel TO; Lehner B; Bernd L; Ewerbeck V; Burger C; Strauss LG
    Eur J Nucl Med; 2001 Jun; 28(6):704-10. PubMed ID: 11440030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions.
    Tian R; Su M; Tian Y; Li F; Li L; Kuang A; Zeng J
    Skeletal Radiol; 2009 May; 38(5):451-8. PubMed ID: 19205695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
    Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
    Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET.
    Watanabe H; Inoue T; Shinozaki T; Yanagawa T; Ahmed AR; Tomiyoshi K; Oriuchi N; Tokunaga M; Aoki J; Endo K; Takagishi K
    Eur J Nucl Med; 2000 Oct; 27(10):1509-17. PubMed ID: 11083540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 11C-choline PET for the detection of bone and soft tissue tumours in comparison with FDG PET.
    Zhang H; Tian M; Oriuchi N; Higuchi T; Watanabe H; Aoki J; Tanada S; Endo K
    Nucl Med Commun; 2003 Mar; 24(3):273-9. PubMed ID: 12612468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions.
    Dimitrakopoulou-Strauss A; Strauss LG; Heichel T; Wu H; Burger C; Bernd L; Ewerbeck V
    J Nucl Med; 2002 Apr; 43(4):510-8. PubMed ID: 11937595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic and static approaches to quantifying 18F-FDG uptake for measuring cancer response to therapy, including the effect of granulocyte CSF.
    Doot RK; Dunnwald LK; Schubert EK; Muzi M; Peterson LM; Kinahan PE; Kurland BF; Mankoff DA
    J Nucl Med; 2007 Jun; 48(6):920-5. PubMed ID: 17504870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions.
    Aoki J; Watanabe H; Shinozaki T; Takagishi K; Ishijima H; Oya N; Sato N; Inoue T; Endo K
    Radiology; 2001 Jun; 219(3):774-7. PubMed ID: 11376267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
    Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
    Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions.
    Gupta N; Gill H; Graeber G; Bishop H; Hurst J; Stephens T
    Chest; 1998 Oct; 114(4):1105-11. PubMed ID: 9792584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical feasibility and impact of fully automated multiparametric PET imaging using direct Patlak reconstruction: evaluation of 103 dynamic whole-body
    Dias AH; Pedersen MF; Danielsen H; Munk OL; Gormsen LC
    Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):837-850. PubMed ID: 32894338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simple quantification of skeletal muscle glucose utilization by static 18F-FDG PET.
    Yokoyama I; Inoue Y; Moritan T; Ohtomo K; Nagai R
    J Nucl Med; 2003 Oct; 44(10):1592-8. PubMed ID: 14530472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of Dynamic [
    Zhao Y; Lv T; Xu Y; Yin J; Wang X; Xue Y; Zhu G; Yu W; Wang H; Li X
    Mol Imaging Biol; 2024 Oct; 26(5):790-801. PubMed ID: 39174787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of intratumoral heterogeneity of (18)F-FDG uptake to differentiate between primary benign and malignant musculoskeletal tumours on PET/CT.
    Nakajo M; Nakajo M; Jinguji M; Fukukura Y; Nakabeppu Y; Tani A; Yoshiura T
    Br J Radiol; 2015; 88(1055):20150552. PubMed ID: 26337605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does whole-body Patlak
    Fahrni G; Karakatsanis NA; Di Domenicantonio G; Garibotto V; Zaidi H
    Eur Radiol; 2019 Sep; 29(9):4812-4821. PubMed ID: 30689031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas.
    Nakamoto Y; Higashi T; Sakahara H; Tamaki N; Kogire M; Doi R; Hosotani R; Imamura M; Konishi J
    Cancer; 2000 Dec; 89(12):2547-54. PubMed ID: 11135214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual time point 2-[18F]fluoro-2'-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis.
    Sahlmann CO; Siefker U; Lehmann K; Meller J
    Nucl Med Commun; 2004 Aug; 25(8):819-23. PubMed ID: 15266177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET.
    Hickeson M; Yun M; Matthies A; Zhuang H; Adam LE; Lacorte L; Alavi A
    Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1639-47. PubMed ID: 12458399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.